Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19


Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia

Full Title of Study: “A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2020


  • Biological: Kamada Anti-SARS-CoV-2
    • Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada’s proprietary purification methods

Arms, Groups and Cohorts

  • Experimental: Immune gamma globulin (IgG)
    • Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion

Clinical Trial Outcome Measures

Primary Measures

  • Adverse events, serious adverse events, and deaths
    • Time Frame: 14 days
    • Record adverse events, serious adverse events, and deaths
  • Adverse events, serious adverse events, and deaths
    • Time Frame: 28 days
    • Record adverse events, serious adverse events, and deaths

Secondary Measures

  • AUC0-7 of Anti SARS CoV-2 antibodies
    • Time Frame: 7 days
    • Measurement of the area under the curve of anti SARS CoV-2 immunoglobulin
  • Neutralization activity
    • Time Frame: 7 days
    • Evaluate virus neutralization activity of patient’s plasma

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 18 years

2. Laboratory confirmed SARS-CoV-2 infection by nasopharyngeal swab Real time polymerase chain reaction (RT-PCR)

3. Hospitalized for COVID-19 pneumonia

4. Dosing should be within 10 days of symptom start

5. Able and willing to sign informed consent form

Exclusion Criteria

1. History of hypersensitivity to plasma products and/or severe Immunoglobulin A deficiency (< 7 mg/dL)

2. Requirement of high flow oxygen devices, or non-invasive ventilation or mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) at screening

3. Cardiovascular instability

4. History of thrombo-embolic events

5. Acute renal failure or creatinine >2 mg/dL or estimated estimated glomerular filtration rate (eGFR) <30 mL/min

6. History of lung transplantation

7. Major surgery (abdominal and chest) within the last 4 weeks

8. Severe chronic background disease, per investigator's judgement for example, Cirrhosis grade C, Dialysis, cardiac insufficiency (NYHA III), pulmonary disease (FEV1<50 percent of predicted) etc.

9. Pregnancy or lactation

10. Treatment with plasma units or immunoglobulin preparations within the last 4 weeks

11. Participation in another pharmaceutical interventional clinical study within 4 weeks from screening

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kamada, Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Sharon Castro, MSc, +972 8 9406472,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.